Who
Gilmore Neil O'Neill
CEO
Company insider
Files Form 4 as: CEO, Editas Medicine; Director, Unity Biotechnology; Director, Aptinyx; EVP, R&D & Cmo, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 46
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $1.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 7 Jun 2018
- Last trade
- 3 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 4 Sep 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $16K5,124 at $3.04 | filing |
| 3 Sep 2026filed 4 Sep 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $16K5,124 at $3.04 | filing |
| 3 Jun 2026filed 5 Jun 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $42K15,380 at $2.70 | filing |
| 3 Jun 2026filed 5 Jun 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $42K15,380 at $2.70 | filing |
| 12 Mar 2026filed 16 Mar 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —1,015,200 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —1,015,200 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $11K5,394 at $2.02 | filing |
| 3 Mar 2026filed 4 Mar 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $11K5,394 at $2.02 | filing |
| 3 Dec 2025filed 4 Dec 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $12K5,603 at $2.15 | filing |
| 3 Sep 2025filed 4 Sep 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $15K5,592 at $2.60 | filing |
| 3 Jun 2025filed 4 Jun 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $26K15,192 at $1.72 | filing |
| 8 Mar 2025filed 27 Mar 2025 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —828,000 at $0.00 | filing |
| 8 Mar 2025filed 27 Mar 2025 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $28K16,632 at $1.71 | filing |
| 3 Dec 2024filed 5 Dec 2024 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $3,3651,618 at $2.08 | filing |
| 4 Sep 2024filed 6 Sep 2024 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $5,3181,555 at $3.42 | filing |
| 21 Jun 2024filed 21 Jun 2024 | Unity Biotechnologyoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $67K12,191 at $5.50 | filing |
| 5 Mar 2024filed 5 Mar 2024 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $733K77,824 at $9.42 | filing |
| 2 Mar 2024filed 5 Mar 2024 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —392,100 at $0.00 | filing |
News
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Sharestickerreport.com · 5 Sep 2026Financial Contrast: Alvotech (NASDAQ:ALVO) & Editas Medicine (NASDAQ:EDIT)EDIT · themarketsdaily.com · 18 Oct 2026Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor ConferenceEDIT · manilatimes.net · 14 Oct 2026
1 headline in the last 90 days name Gilmore Neil O'Neill; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.